scholarly journals Biologics in Paediatric Crohn's Disease

2011 ◽  
Vol 2011 ◽  
pp. 1-10 ◽  
Author(s):  
Oliver Gouldthorpe ◽  
Anthony G. Catto-Smith ◽  
George Alex
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Growth Parameters ◽  
Case Series ◽  
Limited Data ◽  
Childhood Onset ◽  
Biologic Drugs ◽  
Life Therapy

Crohn's disease affects increasing numbers of children worldwide. Generally, childhood-onset disease runs a more severe course than in adults and has a greater impact on quality of life. Therapy in children must take account of a different set of risks for toxicity compared to adults, but also to their longevity. Biologic drugs present remarkable advantages in terms of disease control for children, especially in those whose disease cannot be controlled with conventional therapies, but their long-term risks are still being assessed. Data regarding biologic use in children is limited and mostly amounts to case series, but results have been promising, both in terms of controlling disease activity and improving growth parameters. Adverse reactions are infrequent in the short term, but loss of response is a long-term problem, particularly in children. More information is needed about very long term risks. Infliximab and adalimumab are the most studied agents in children, while there is relatively limited data on certolizumab and natalizumab. Further collection of data on these agents is still needed, but this should not restrict access to these agents for children in whom no other agent is effective.

scholarly journals Long-term prognosis in Crohn's disease: factors that affect quality of life

2006 ◽  
Vol 23 (3) ◽  
pp. 377-385 ◽  
Author(s):  
C. CANAVAN ◽  
K. R. ABRAMS ◽  
B. HAWTHORNE ◽  
D. DROSSMAN ◽  
J. F. MAYBERRY
Keyword(s):  
Quality Of Life ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Long Term Prognosis

Mo1470 Factors Associated With Long-Term Quality of Life (QL) After Ileocolic Resection (ICR) for Crohn's Disease

2012 ◽  
Vol 142 (5) ◽  
pp. S-1072
Author(s):  
Felipe Bellolio ◽  
Zane Cohen ◽  
Helen M. MacRae ◽  
J.Charles Victor ◽  
Brenda I. O'Connor ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Ileocolic Resection ◽  
Factors Associated

The Impact of Cholecystectomy on Long-Term Disease Outcomes and Quality of Life in Patients with Crohn’s Disease

2020 ◽  
Author(s):  
Filippos Koutroumpakis ◽  
Maham Lodhi ◽  
Maaz Ahsan ◽  
Claudia Ramos Rivers ◽  
Marc Schwartz ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Disease Activity ◽  
Hospital Admissions ◽  
Tertiary Center ◽  
Prospective Longitudinal ◽  
The Impact

Abstract Background Cholecystectomy (CCY) is one of the most frequently performed abdominal surgeries. However, the impact of CCY in clinical settings with altered gastrointestinal physiology and anatomy, such as Crohn’s disease (CD), has not been fully characterized. We sought to investigate clinical outcomes, disease severity, and quality of life of CD patients after CCY. Methods We utilized a prospective, longitudinal registry of consented CD patients followed at a tertiary center. Crohn’s disease patients that had or had not undergone CCY formed the 2 study groups. The absence or presence of gallbladder was confirmed with abdominal CT scans obtained during routine care. Multiyear clinical, biochemical, and histologic data were collected and analyzed. Results Among 834 CD patients, 151 (18%) had undergone CCY. History of CCY was associated with higher disease activity (median Harvey-Bradshaw index; P < 0.001), more years with anemia (P = 0.048), lower albumin (P = 0.001), worse quality of life (mean Short Inflammatory Bowel Disease Questionnaire; P < 0.001), chronic abdominal pain (P < 0.001), higher risk for incident colonic dysplasia (P = 0.011), higher rates of annual hospital admissions (P = 0.004), and opioid use (P < 0.001). In multivariate analysis, CCY remained associated with higher disease activity (P < 0.001), lower albumin (P = 0.008), lower quality of life (P < 0.001), and more hospital admissions (P = 0.008), whereas CD patients with diseased ileum had higher risk for colonic dysplasia (P = 0.031). Conclusions CCY in CD patients was associated with multiple markers of disease activity and worse quality of life during multiyear follow up. This data suggests that CCY in CD patients may adversely impact the long-term clinical course.

scholarly journals Mesenchymal Stromal Cell Therapy in the Management of Perianal Fistulas in Crohn’s Disease: An Up-To-Date Review

Medicina ◽  
2020 ◽  
Vol 56 (11) ◽  
pp. 563
Author(s):  
Gaetano Gallo ◽  
Vincenzo Tiesi ◽  
Serena Fulginiti ◽  
Gilda De Paola ◽  
Giuseppina Vescio ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Stromal Cells ◽  
Tissue Repair ◽  
Negative Impact ◽  
Inflammatory Disorder ◽  
Chronic Inflammatory Disorder ◽  
Entire Gastrointestinal Tract

Crohn’s Disease (CD) is a chronic inflammatory disorder that potentially involves the entire gastrointestinal tract. Perianal fistulizing CD (pCD) is a serious and frequent complication associated with significant morbidities and a heavy negative impact on quality of life. The aim of CD treatment is to induce and maintain disease remission and to promote mucosal repair. Unfortunately, even the best therapeutic regimens in pCD do not have long-term efficacy and cause a significant number of side effects. Therefore, it is mandatory to study new therapeutical options such as the use of mesenchymal stromal cells (MSCs). These cells promote tissue repair via the induction of immunomodulation. The present review aims to analyze the existing updated scientific literature on MSCs adoption in the treatment of pCD to evaluate its efficacy and safety and to compare the use of bone marrow and adipose tissue derived MSCs, type of administration, and dose required for recovery.

scholarly journals Certolizumab pegol for the treatment of Crohn’s disease

2011 ◽  
Vol 4 (6) ◽  
pp. 375-389 ◽  
Author(s):  
Stefan Schreiber
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Certolizumab Pegol ◽  
Fixed Dose ◽  
Sustained Remission ◽  
Early Therapy ◽  
Rapid Induction ◽  
Clinical Trial Program

In this article we provide a contemporary overview of available clinical data on certolizumab pegol, a pegylated anti-tumor necrosis factor (TNF) alpha agent that comprises a uniquely small protein, and its emerging role as a therapy for Crohn’s disease (CD). The results from a comprehensive clinical trial program suggest that certolizumab pegol offers rapid and sustained remission of moderate to severe CD. Certolizumab pegol is an effective and well-tolerated therapy both in patients who have already received biologics and in patients who are anti-TNF naïve. Benefits of therapy include a stable dosing regimen, which allows for rapid induction of a clinical response followed by long-term maintenance of response and remission under one fixed dose. Treatment with certolizumab pegol has been shown to improve function and quality of life in patients with CD, and insights into the potential mechanisms by which certolizumab pegol effects a response in CD suggest that this agent may have the potential to slow or even modify disease progression. Early therapy is particularly effective and could help control CD progression and lessen the burden of disease on patients.

Assessment of long-term quality of life after laparoscopic and open surgery for Crohn's disease

2005 ◽  
Vol 7 (4) ◽  
pp. 375-381 ◽  
Author(s):  
K. Thaler ◽  
A. Dinnewitzer ◽  
M. Oberwalder ◽  
E. G. Weiss ◽  
J. J. Nogueras ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Open Surgery
Sign in / Sign up

Export Citation Format

Share Document